Table 5.
Demographics, treatment, and clinical outcomes of infectious keratitis cases seen from 2009 to 2013 (n=35)
| Characteristic | Result |
|---|---|
| Age | |
| Mean (yr) | 54 |
| Gender | |
| Female | 22 (63%) |
| Male | 13 (37%) |
| Eye | |
| OD | 14 (40%) |
| OS | 14 (40%) |
| OD/OS | 1 (3%) |
| Missing | 6(17%) |
| Predisposing factors | |
| Corneal transplant | 5 (14%) |
| Soft contact lens wearer | 3 (9%) |
| Bullous keratopathy | 3 (9%) |
| Rigid contact lens wearer | 1 (3%) |
| Allergic conjunctivitis | 1 (3%) |
| Corneal trauma | 1 (3%) |
| Entropium, trichiasis | 1 (3%) |
| Trachoma | 1 (3%) |
| Dry eye syndrome | 1 (3%) |
| Neurotrophic ulcer | 1 (3%) |
| Missing | 10 (29%) |
| Previous surgery | |
| Phacoemulsification | 10 (29%) |
| Glaucoma | 3 (9%) |
| Retinal detachment | 2 (6%) |
| Treatment | |
| Topical MOX | 6(17%) |
| MOX, DOX, therapeutic lens | 2 (6%) |
| MOX, DOX | 1 (3%) |
| MOX, therapeutic lens, and AC washing | 1 (3%) |
| MOX, glue, and therapeutic lens | 1 (3%) |
| MOX and ERY ointment | 1 (3%) |
| Topical MOX and GEN, endovenous AMI and CEF | 1 (3%) |
| Topical MOX; CEF and TOB (fortified) | 1 (3%) |
| MOX; subconjunctival injection VAN; oral C1P and cefazoline | 1 (3%) |
| MOX, OFLOX | 1 (3%) |
| OFLOX and therapeutic lens | 1 (3%) |
| OFLOX | 1 (3%) |
| C1P, propamidine, and chlorhexidine | 1 (3%) |
| C1P | 1 (3%) |
| GAT | 1 (3%) |
| CTX and endovenous CLIN | 1 (3%) |
| Missing | 13 (37%) |
| VA outcome | |
| 20/70 | 1 (3%) |
| 20/100 | 1 (3%) |
| 20/200 | 3 (9%) |
| HM | 6(17%) |
| LP | 1 (3%) |
| NLP | 6(17%) |
| Missing | 17 (49%) |